Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma

NCT05864742 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma Refractory

Interventions

DRUG: Ibrutinib
DRUG: Venetoclax
DRUG: Navitoclax
DRUG: Rituximab

Sponsor

Peter MacCallum Cancer Centre, Australia